James M Reuben
Overview
Explore the profile of James M Reuben including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
6906
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwase T, Parikh A, Wenli D, Shen Y, Adams D, Tang C, et al.
J Cancer
. 2024 Oct;
15(18):5855-5862.
PMID: 39440056
Cancer-associated macrophage-like cells (CAMLs) are rare, gigantic, and atypical circulating cells found exclusively in the peripheral blood of patients with solid cancers. Obesity-induced hypoxia attracts macrophages to the tumor microenvironment,...
2.
Lee J, Kida K, Koh J, Liu H, Manyam G, Gi Y, et al.
J Exp Clin Cancer Res
. 2024 Aug;
43(1):236.
PMID: 39164784
Background: Anti-HER2 therapies, including the HER2 antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have led to improved survival outcomes in patients with HER2-overexpressing (HER2+) metastatic breast cancer....
3.
Iwase T, Cohen E, Gao H, Alexander A, Kai M, Chiv V, et al.
Clin Cancer Res
. 2024 Apr;
30(11):2424-2432.
PMID: 38629963
Purpose: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy...
4.
Cohen E, Jayachandran G, Gao H, Peabody P, McBride H, Alvarez F, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900406
Circulating tumor cells (CTCs) are indicators of metastatic spread and progression. In a longitudinal, single-center trial of patients with metastatic breast cancer starting a new line of treatment, a microcavity...
5.
Cohen E, Jayachandran G, Gao H, Peabody P, McBride H, Alvarez F, et al.
Transl Lung Cancer Res
. 2023 Feb;
12(1):109-126.
PMID: 36762061
Background: Circulating tumor cells (CTCs) are a promising non-invasive tool for monitoring therapy response. The only Food and Drug Administration (FDA)-approved test is limited to enumeration of epithelial CTC without...
6.
Wang X, Semba T, Manyam G, Wang J, Shao S, Bertucci F, et al.
Sci Adv
. 2022 Dec;
8(50):eabn7983.
PMID: 36525493
Inflammatory breast cancer (IBC), the most aggressive breast cancer subtype, is driven by an immunosuppressive tumor microenvironment (TME). Current treatments for IBC have limited efficacy. In a clinical trial (NCT01036087),...
7.
Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang J, Khoury J, et al.
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358657
Circulating tumor cells (CTCs) captured from the blood of cancer patients may serve as a surrogate source of tumor material that can be obtained via a venipuncture (also known as...
8.
Wu L, Dai P, Wang M, Chen S, Cohen E, Jayachandran G, et al.
Nat Commun
. 2022 Apr;
13(1):1791.
PMID: 35379811
Current gold standard for absolute quantitation of a specific DNA sequence is droplet digital PCR (ddPCR), which has been applied to copy number variation (CNV) detection. However, the number of...
9.
Gerratana L, Pierga J, Reuben J, Davis A, Wehbe F, Dirix L, et al.
Oncologist
. 2022 Mar;
27(7):e561-e570.
PMID: 35278078
Despite the strong prognostic stratification of circulating tumor cells (CTCs) enumeration in metastatic breast cancer (MBC), current clinical trials usually do not include a baseline CTCs in their design. This...
10.
Yennurajalingam S, Valero V, Lu Z, Liu D, Busaidy N, Reuben J, et al.
J Natl Compr Canc Netw
. 2021 Dec;
20(3):235-243.
PMID: 34965510
Background: Despite the high frequency of cancer-related fatigue (CRF) and its debilitating effects on the quality of life of patients with advanced cancer, there are limited treatment options available. Treatments...